In
cancer therapy the
platinum-based drugs are used frequently with a good clinical outcome, but besides unwanted side effects which occur, the tumour cells subjected to treatment are prone to develop tolerance or even multidrug resistance (MDR).
Metal compounds with a central atom other than
platinum are efficient in targeting the chemoresistant cells, therefore the
biological outcome of two recently synthesized
gallium phosphinoarylbisthiolato complexes was studied, having the formula [X][Ga{PPh(2-SC6H4)2-κ(3)S,S',P}{PPh(2-SC6H4)2-κ(2)S,S'}] where [X] is either the NEt3H (1) or PPh4 (2)
cation. Compounds 1 and 2 display in vitro cytotoxicity against both
platinum-sensitive and
platinum-resistant cell lines (A2780 and A2780cis). Morphological and ultrastructural evidence points toward their capacity to impair tumour cells survival. This behaviour is based on malignant cells capacity to selectively intake
gallium, and to bind to the cellular
DNA. They are able to cause massive DNA damage in treated
cancer cells, focusing on
7-methylguanine and
8-oxoguanine sites and oxidizing the
pyrimidine bases; this leads to early apoptosis of a significant percent of treated cells. The intrinsic and extrinsic apoptotic pathways are influenced through the modulation of gene expression following the treatment with complexes 1 and 2, which accompanies the negative regulation of
P-glycoprotein 1 (Pgp-1), an important cellular ABC-type transporter from the multidrug resistance (MDR) family. The studied Ga(III) compounds demonstrated the capacity to counteract the chemoresistance mechanisms in the tumours defiant to standard
drug action. Compound 2 shows a good anticancer potential and it could represent an alternative to
platinum-based drugs especially in the situation of standard treatment failure.